Remifentanil and Desflurane Inhalational Anesthesia in Bariatric Surgeries
Summary
The number of obese and overweighted persons doubled since 1980. They are 600 million in 2014 all over the world. Obesity results in anatomical, physiological and pharmacological changes which represent a challenge for every anesthetist. Difficult airway increases by 30% with obesity and so awake extubation are the preferred technique. Coughing can be alleviated by opioid receptors which play a role in the cough reflex. Remifentanil may be useful as an ultra-short acting opioid and its effect swiftly and predictably disappears after cessation. An emergence cough is attenuated by remifentanil administered via continuous infusion (TCI), and the expected effective effect-site concentrations investigated have ranged from 1.5 to 2.5 ng.ml/L.
Timeline
- Start
- 2017-07-20
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Remifentanil | Small molecule | 0.1 ug/kg | — |
| Comparator | Remifentanil | Small molecule | 0.2 ug/kg | — |
Indications
No indication recorded.